Please wait while the formulary information is being retrieved.
Drug overview for OXANDRIN (oxandrolone):
Generic name: OXANDROLONE (ox-AN-droe-lone)
Drug class: Androgens/Anabolic Steroids
Therapeutic class: Endocrine
Oxandrolone is a synthetic androgenic anabolic steroid hormone.
No enhanced Uses information available for this drug.
Generic name: OXANDROLONE (ox-AN-droe-lone)
Drug class: Androgens/Anabolic Steroids
Therapeutic class: Endocrine
Oxandrolone is a synthetic androgenic anabolic steroid hormone.
No enhanced Uses information available for this drug.
DRUG IMAGES
OXANDRIN 2.5 MG TABLET
OXANDRIN 10 MG TABLET
The following indications for OXANDRIN (oxandrolone) have been approved by the FDA:
Indications:
Catabolic process
Professional Synonyms:
Catabolism
Indications:
Catabolic process
Professional Synonyms:
Catabolism
The following dosing information is available for OXANDRIN (oxandrolone):
No enhanced Dosing information available for this drug.
Oxandrolone is administered orally 2 to 4 times daily in adults. The drug usually is administered once daily in pediatric patients.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for OXANDRIN (oxandrolone):
There are 0 contraindications.
There are 4 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Selected Anticoagulants (Vitamin K antagonists)/Oxandrolone SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Oxandrolone is a CYP2C9 inhibitor and can inhibit metabolism of warfarin and other anticoagulants by this(1) and perhaps other metabolic pathways. CLINICAL EFFECTS: The concurrent use of an anticoagulant and oxandrolone may increase the risk for bleeding episodes. PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). Patients with a CYP2C9 intermediate metabolizer genotype, and/or 1-2 copies of a reduced function VKORC1 gene are expected to be more susceptible to this interaction. Although patients with a pre-existing CYP2C9 poor metabolizer genotype are expected to be less susceptible to effects from this drug combination, their reduced function genotypes (e.g. CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3) result in an inherently higher warfarin half-life and risk for warfarin-associated bleeding. CYP2C9 poor metabolizers generally require lower anticoagulant doses and more time (>2 to 4 weeks) to achieve effective and safe anticoagulation than patients without these CYP2C9 variants.(2) PATIENT MANAGEMENT: Close monitoring and anticoagulant dose adjustment should be performed until patients have been stabilized on the combination. Patients on a stabile anticoagulant dose when oxandrolone therapy is started are at risk for supratherapeutic anticoagulation and bleeding episodes. In an interaction study, warfarin dose reductions of approximately 80% were required to maintain therapeutic INRs.(3) If warfarin is started in a patient already receiving oxandrolone, start with a low anticoagulant dosage. In a warfarin-oxandrolone interaction study performed in healthy adults, doses of 0.75 - 1.5 mg daily maintained subjects at targeted INR values of 1.5.(3) If oxandrolone is subsequently discontinued, additional monitoring is needed to assure adequate anticoagulation. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: In a study in 15 healthy subjects, oxandrolone increased the half-life of S-warfarin from 26 to 48 hours and increased the area-under-curve (AUC) of S-warfarin by 1.7-fold. Although not metabolized by CYP2C9, similar effects on R-warfarin were noted. Subjects required an 80-85% reduction in warfarin dosage, from a mean dose of 6.13 mg daily to 1.13 mg daily, to maintain a target INR of 1.5. Microscopic hematuria was observed in 9 subjects and gingival bleeding was observed in another.(3) The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated, altered, or discontinued. |
ANISINDIONE, DICUMAROL, JANTOVEN, PHENINDIONE, WARFARIN SODIUM |
| Bosentan/Strong and Moderate CYP2C9 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Bosentan is metabolized by CYP2C9 and CYP3A4. It is also an inducer of these enzymes. With regular dosing bosentan auto-induces its own metabolism.(1) Strong and moderate CYP2C9 inhibitors may inhibit the CYP2C9 mediated metabolism of bosentan.(2) CLINICAL EFFECTS: Concurrent use of bosentan with an inhibitor of CYP2C9 may result in elevated levels of and toxicity from bosentan.(3) PREDISPOSING FACTORS: Concurrent use of bosentan, a CYP2C9 inhibitor and a CYP3A4 inhibitor (e.g. aprepitant, boceprevir, ceritinib, ciprofloxacin, clarithromycin, conivaptan, crizotinib, cyclosporine, darunavir, diltiazem, dronedarone, erythromycin, fluconazole, fosaprepitant, idelalisib, imatinib, isavuconazole, itraconazole, ketoconazole, letermovir, mibefradil, nefazodone, netupitant, nilotinib, posaconazole, ribociclib, telaprevir, telithromycin, troleandomycin, verapamil, and voriconazole)(3) could lead to blockade of both major metabolic pathways for bosentan, resulting in large increases in bosentan plasma concentrations.(3) PATIENT MANAGEMENT: Review medication list to see if patient is also receiving a CYP3A4 inhibitor (e.g. aprepitant, boceprevir, ceritinib, ciprofloxacin, clarithromycin, conivaptan, crizotinib, cyclosporine, darunavir, diltiazem, dronedarone, erythromycin, fluconazole, fosaprepitant, idelalisib, imatinib, isavuconazole, itraconazole, ketoconazole, letermovir, mibefradil, nefazodone, netupitant, nilotinib, posaconazole, ribociclib, telaprevir, telithromycin, troleandomycin, verapamil, and voriconazole). Concomitant use of both a CYP2C9 and CYP3A4 inhibitor is not recommended by the manufacturer as the combination may lead to large increases in bosentan plasma concentrations.(1) For patients stabilized on bosentan when a CYP2C9 inhibitor is initiated, monitor tolerance to concomitant therapy and adjust bosentan dose if needed. DISCUSSION: Concurrent use with CYP2C9 inhibitors has not been studied. In a study in healthy subjects, concurrent bosentan and ketoconazole, a strong CYP3A4 inhibitor, administration increased bosentan steady-state maximum concentrations (Cmax) and area-under-curve (AUC) by 2.1-fold and 2.3-fold, respectively.(2) Strong CYP2C9 inhibitors linked to this monograph include: miconazole.(3) Moderate CYP2C9 inhibitors linked to this monograph include: amiodarone, apazone, asciminib, benzbromarone, cannabidiol, nitisinone, oxandrolone, piperine, sulfaphenazole, and phenylbutazone.(3) |
BOSENTAN, TRACLEER |
| Siponimod/Selected Moderate CYP2C9 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inhibitors of CYP2C9 may inhibit the metabolism of siponimod.(1) CLINICAL EFFECTS: Concurrent use of an inhibitor of CYP2C9 may result in elevated levels of and clinical effects of siponimod, including immunosuppression and increased risk of infection.(1) Concurrent use of siponimod with immunosuppressive or immune-modulating agents, such as asciminib, may result in an additive risk and increased risk of serious infections. PREDISPOSING FACTORS: Concurrent use of a strong or moderate inhibitor of CYP3A4 may increase the effects of the interaction. PATIENT MANAGEMENT: Concurrent use of an inhibitor of CYP2C9 with siponimod is not recommended in patients also taking a strong or moderate inhibitor of CYP3A4.(1) Review the patient's therapy for concurrent use of strong or moderate inhibitors of CYP3A4 prior to initiating siponimod. DISCUSSION: Siponimod is metabolized by CYP2C9 (79.3%) and CYP3A4 (18.5%). Concurrent use of fluconazole (a dual moderate inhibitor of CYP2C9 and CYP3A4, 200 mg at steady state) in healthy subjects with the CYP2C9*1/*1 genotype increased the area-under-curve (AUC) of siponimod (4 mg single dose) by 2-fold. Siponimod half-life increased by 50%. Fluconazole increased siponimod AUC by 2-fold to 4-fold across all CYP2C9 genotypes.(1) Selected moderate CYP2C9 inhibitors linked to this monograph include: apazone, asciminib, benzbromarone, cannabidiol, felbamate, miconazole, milk thistle, nitisinone, oxandrolone, phenylbutazone, piperine, silibinin, and sulfaphenazole.(2) |
MAYZENT |
| Erdafitinib/Strong CYP3A4 or Moderate CYP2C9 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Erdafitinib is metabolized by CYP3A4 and CYP2C9. Strong inhibitors of CYP3A4 or moderate inhibitors of CYP2C9 may inhibit the metabolism of erdafitinib.(1) CLINICAL EFFECTS: Concurrent use of strong CYP3A4 or moderate CYP2C9 inhibitors may increase the levels and effects of erdafitinib, including retinopathy and hyperphosphatemia.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US prescribing information states that concurrent use of erdafitinib with strong CYP3A4 inhibitors or moderate CYPC9 inhibitors should be avoided. If concurrent use cannot be avoided, monitor closely for adverse reactions and consider a dose modification based on prescribing information. If the strong CYP3A4 or moderate CYP2C9 inhibitor is discontinued, consider increasing the erdafitinib dose if patient does not have any drug-related toxicity.(1) DISCUSSION: In PKPB models, concurrent use of fluconazole (a moderate CYP2C9 and CYP3A4 inhibitor) resulted in erdafitinib mean ratios for concentration maximum (Cmax) and area-under-curve (AUC) of 121% and 148% , respectively, compared to erdafitinib alone.(1) In PKPB models, concurrent use of itraconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) resulted in erdafitinib mean ratios for Cmax and AUC of 105% and 134%, respectively, compared to erdafitinib alone.(1) Strong inhibitors of CYP3A4 include: adagrasib, boceprevir, ceritinib, clarithromycin, cobicistat, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, levoketoconazole, lonafarnib, lopinavir, mibefradil, mifepristone, nefazodone, nelfinavir, nirmatrelvir, paritaprevir, posaconazole, ribociclib, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, tucatinib, and voriconazole.(2,3) Moderate inhibitors of CYP2C9 include: adagrasib, amiodarone, apazone, asciminib, benzbromarone, cannabidiol, fluconazole, miconazole, mifepristone, milk thistle, nitisinone, oxandrolone, phenylbutazone, and sulfaphenazole.(2,3) |
BALVERSA |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Selected NSAIDs/Selected CYP2C9 Inhibitors SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The major metabolic pathway for many non-steroidal anti-inflammatory agents (NSAIDs) is CYP2C9. Inhibitors of CYP2C9 include: amiodarone, asciminib, cannabidiol, diosmin, fluconazole, ketoconazole, miconazole, nitisinone, oxandrolone, piperine, voriconazole, and zafirlukast.(1,2) CLINICAL EFFECTS: Concurrent use of NSAIDs with inhibitors of CYP2C9 may result in increased levels of and adverse effects from NSAIDs, including increased risk for bleeding. NSAIDs linked to this monograph are celecoxib, diclofenac, flurbiprofen, ibuprofen, meloxicam, naproxen, parecoxib, piroxicam and valdecoxib. PREDISPOSING FACTORS: Higher doses of either agent would be expected to increase the risk for serious adverse effects such as gastrointestinal bleeding (GIB) or renal failure. Patients who smoke, are elderly, debilitated, dehydrated, have renal impairment, or who have a history of GIB due to NSAIDs are also at increased risk for serious adverse events.(3-7) The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: Patients on routine NSAID therapy when an inhibitor of CYP2C9 is started should be evaluated for patient-specific risk factors for NSAID toxicity. Based upon this risk assessment, consider dose reduction of the NSAID or close monitoring for adverse effects. For a patient already receiving a CYP2C9 inhibitor when an NSAID is started, consider initiating the NSAID at a lower than usual dose, particularly when predisposing risk factors for harm are present. The manufacturer of celecoxib recommends that celecoxib be introduced at the lowest recommended dose in patients receiving fluconazole therapy.(3) The manufacturer of fluconazole states that half the dose of celecoxib may be necessary when fluconazole is added.(4) It would be prudent to follow this recommendation with other CYP2C9 inhibitors and to decrease the dose of celecoxib in patients in whom CYP2C9 inhibitors are added to celecoxib therapy. The manufacturer of diclofenac-misoprostol states that the total daily dose of diclofenac should not exceed the lowest recommended dose of 50 mg twice daily in patients taking CYP2C9 inhibitors.(5) It would be prudent to use the lowest recommended dose of other diclofenac formulations in patients taking CYP2C9 inhibitors. The manufacturer of parecoxib states that the dose of parecoxib should be reduced in those patients who are receiving fluconazole therapy.(6) It would be prudent to follow this recommendation with other CYP2C9 inhibitors. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. DISCUSSION: The concomitant administration of celecoxib and fluconazole (200 mg daily) resulted in a 2-fold increase in celecoxib plasma concentration.(3) In vitro studies in human hepatocytes found that amiodarone inhibited diclofenac metabolism.(7) In two separate studies, single doses of diclofenac (50 mg) or ibuprofen (400 mg) were coadministered with the last dose of voriconazole (400 mg q12h on Day 1, followed by 200 mg q12h on Day 2). Voriconazole increased the mean AUC of diclofenac by 78% and increased the AUC of the active isomer of ibuprofen by 100%.(8-10) Coadministration of diosmin increased diclofenac levels by 63%.(2) Coadministration of flurbiprofen or ibuprofen with fluconazole increased the AUC of flurbiprofen by 81% and of the active ibuprofen by 82% compared with either agent alone.(4) Concurrent voriconazole increased meloxicam AUC by 47%.(11,12) The concurrent administration of fluconazole and parecoxib resulted in increases in the area-under-curve (AUC) and maximum concentration (Cmax) of valdecoxib (the active metabolite of parecoxib) by 62% and 19%, respectively.(6) In a study, single dose diclofenac (50mg) given concurrently with the last dose of voriconazole (400 mg every 12 hours on Day 1, 200 mg every 12 hours on Day 2) increased Cmax and AUC by 2.1-fold and 1.8-fold, respectively. (5) Inhibitors of CYP2C9 include: amiodarone, asciminib, cannabidiol, diosmin, fluconazole, ketoconazole, miconazole, nitisinone, oxandrolone, piperine, voriconazole, and zafirlukast.(1,2) |
ANAPROX DS, ANJESO, ARTHROTEC 50, ARTHROTEC 75, CALDOLOR, CAMBIA, CELEBREX, CELECOXIB, COMBOGESIC, COMBOGESIC IV, CONSENSI, DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM ER, DICLOFENAC SODIUM MICRONIZED, DICLOFENAC SODIUM-MISOPROSTOL, EC-NAPROSYN, ELYXYB, FELDENE, FLURBIPROFEN, HYDROCODONE-IBUPROFEN, IBU, IBUPAK, IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN-FAMOTIDINE, INFLAMMACIN, INFLATHERM(DICLOFENAC-MENTHOL), LOFENA, LURBIPR, MELOXICAM, NAPRELAN, NAPROSYN, NAPROTIN, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM CR, NAPROXEN SODIUM ER, NAPROXEN-ESOMEPRAZOLE MAG, NEOPROFEN, PIROXICAM, SUMATRIPTAN SUCC-NAPROXEN SOD, SYMBRAVO, TOXICOLOGY SALIVA COLLECTION, TRESNI, TREXIMET, VIMOVO, VIVLODEX, ZIPSOR, ZORVOLEX, ZYNRELEF |
| Lesinurad/Moderate CYP2C9 Inhibitors SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Moderate inhibitors of CYP2C9 may inhibit the metabolism of lesinurad.(1) CLINICAL EFFECTS: Concurrent use of moderate inhibitors of CYP2C9 may result in elevated levels and toxicity from lesinurad, include nephrotoxicity.(1) PREDISPOSING FACTORS: Patients with decreased renal function (CrCl less than 60 ml/min) and patients not receiving a xanthine oxidase inhibitor may be at increased risk of nephrotoxicity.(1) PATIENT MANAGEMENT: Approach the concurrent use of lesinurad and moderate inhibitors of CYP2C9 with caution.(1) Monitor renal function in patients receiving concurrent therapy closely. Interrupt therapy and measure serum creatinine promptly in patients who report flank pain and/or nausea/vomiting. DISCUSSION: Fluconazole (200 mg daily), a moderate inhibitor of CYP2C9, increased lesinurad levels by 50%.(1) |
DUZALLO |
The following contraindication information is available for OXANDRIN (oxandrolone):
Drug contraindication overview.
Males with breast cancer or known or suspected prostate cancer. Women with hypercalcemia associated with metastatic breast cancer. Women with known or suspected pregnancy. Patients with nephrosis or hypercalcemia.
Males with breast cancer or known or suspected prostate cancer. Women with hypercalcemia associated with metastatic breast cancer. Women with known or suspected pregnancy. Patients with nephrosis or hypercalcemia.
There are 7 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Hypercalcemia |
| Lactation |
| Malignant tumor of male breast |
| Neoplasm of liver |
| Nephrotic syndrome |
| Pregnancy |
| Prostatic carcinoma |
There are 4 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Atherosclerotic cardiovascular disease |
| Benign prostatic hyperplasia |
| Chronic heart failure |
| Disease of liver |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Edema |
| High density lipoprotein deficiency |
| Hypercholesterolemia |
| Increased risk of bleeding due to coagulation disorder |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for OXANDRIN (oxandrolone):
Adverse reaction overview.
Elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations).
Elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations).
There are 22 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Priapism Virilism |
Benign prostatic hyperplasia Edema Hypercalcemia Prostatic carcinoma |
| Rare/Very Rare |
|---|
|
Acute myocardial infarction Cerebrovascular accident Cholestatic hepatitis Drug-induced hepatitis Epididymitis Heart failure Hepatic necrosis Hyperbilirubinemia Hyperlipidemia Increased alanine transaminase Increased aspartate transaminase Jaundice Malignant neoplasm of liver Oligospermia Peliosis hepatis Venous thrombosis |
There are 22 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acne vulgaris Bladder irritability Gynecomastia Mastalgia |
Abdominal distension Chills Cramps in legs Diarrhea Gastrointestinal irritation Insomnia Libido changes |
| Rare/Very Rare |
|---|
|
Aggressive behavior Anorexia Clitoral hypertrophy Depression Excitement Fatigue Hostility Irritability Menstrual disorder Skin pigmentation enhancement Testicular atrophy |
The following precautions are available for OXANDRIN (oxandrolone):
May accelerate bone maturation without producing compensatory gain in linear growth, possibly resulting in compromised adult stature. The younger the child, the greater the risk of the drug compromising final mature stature. Use with extreme caution in children and only under the supervision of a specialist who is aware of the adverse effects of oxandrolone on bone maturation. Perform radiographic examination of the left hand and wrist every 6 months to determine rate of bone maturation and to assess the effect of treatment on epiphyseal centers.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category X. May cause fetal harm; potential for virilization of fetus. Fetotoxicity, embryotoxicity, infertility, and virilization of female offspring demonstrated in animals.
Not known whether oxandrolone is distributed into milk. Discontinue nursing or the drug, taking into account the importance of the drug to the woman.
Possible increased risk of developing prostatic hypertrophy and prostate cancer during androgen therapy. Response in patients 65 years of age or older does not appear to differ from that in younger adults. Increased sensitivity to fluid retention and increases in hepatic transaminase values reported, particularly in geriatric women. Use lower dosage to minimize adverse effects.
The following prioritized warning is available for OXANDRIN (oxandrolone):
WARNING: Rarely, this drug has caused serious, sometimes fatal liver problems including liver failure, liver cysts, and liver tumors. Tell your doctor promptly if you have any signs of liver problems such as stomach/abdominal pain that is sudden or doesn't go away, yellowing eyes/skin, dark urine or unusual tiredness. This drug may also affect your cholesterol and may increase your risk of heart or blood vessel problems (coronary artery disease). Your doctor will monitor your cholesterol level closely.
WARNING: Rarely, this drug has caused serious, sometimes fatal liver problems including liver failure, liver cysts, and liver tumors. Tell your doctor promptly if you have any signs of liver problems such as stomach/abdominal pain that is sudden or doesn't go away, yellowing eyes/skin, dark urine or unusual tiredness. This drug may also affect your cholesterol and may increase your risk of heart or blood vessel problems (coronary artery disease). Your doctor will monitor your cholesterol level closely.
The following icd codes are available for OXANDRIN (oxandrolone)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool